Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1545-1551

  Rustin, G J ^a   Nelstrop, A E ^a   McClean, P ^a   Brady, M F ^a   McGuire, W P ^a   Hoskins, W J ^a   Mitchell, H ^a   Lambert, H E ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029961618     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1545     Document Type: Article

References (23)

1. Bast RC, Klug TL, John ES, et al: A radioiummunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:883-887, 1983
2. van der Burg MEL, Lammes FB, Verweij J: CA125 in ovarian cancer. Netherlands J Med 40:36-51, 1992
3. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
4. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
5. Blessing JA: Design, analysis and interpretation of chemotherapy trials in gynecologic cancer, in Deppe G (ed): Chemotherapy of Gynecologic Cancer (ed 2). New York, NY, Liss, 1990, pp 63-97
6. Rustin GJS, van der Burg MEL, Berek JS: Tumour markers. Ann Oncol 4:71-77, 1993 (suppl 4)
7. Ng LW, Homesley HD, Barrett RJ, et al: CA125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. Am J Clin Oncol 12:106-109, 1989
8. Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
9. Markman MA: Proposal to use CA125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecol Oncol 52:297-298, 1993
10. Lambert HE, Rustin GJS, Gregory WM, et al. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: A North Thames Ovary Group study. J Clin Oncol 11:440-448, 1993
11. McGuire WP, Hoskins WJ, Brady MF, et al: An assessment of dose intense therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
12. Searle F, Boden J, Lewis JCM, et al: A human choriocarcinoma xenograft in nude mice; A model for the study of antibody localization. Br J Cancer 44:137-144, 1981
13. Vergote IB, Bormer OP, Abeler VM: Evaluation of serum CA125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 69:223-227, 1987
14. Lavin PT, Knapp RC, Malkasian G, et al: CA125 for the monitoring of ovarian carcinoma during primary treatment. Obstet Gynaecol 69:223-227, 1987
15. Morgensen O: Prognostic value of CA125 in advanced ovarian cancer. Gynaecol Oncol 44:207-212, 1992
16. van der Burg MEL, Lammes FB, van Putten WLJ, et al: Ovarian cancer: the prognostic value of serum half-life of CA125 during induction chemotherapy. Gynaecol Oncol 30:307-312, 1988
17. Rustin GJS, Gennings JN, Nelstrop AE, et al: Use of CA125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 7:1667-1671, 1989
18. Fayers PM, Rustin GJS, Wood R, et al: The prognostic value of serum CA125 in patients with advanced ovarian carcinoma: An analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynaecol Cancer 3:285-292, 1993
19. Rustin GJS, Nelstrop A, Stilwell MA, et al: Savings obtained by CA125 measurements during therapy for ovarian carcinoma. Eur J Cancer 28:79-82, 1992
20. Warr D, McKinney S, Tannock I: Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response. J Clin Oncol 2:1040-1046, 1984
21. Pujade-Lauraine E, Piccart M, Rustin GJS, et al: Comparison of CA125 kinetics and WHO criteria to evaluate chemotherapy response (R): An EORTC ovarian cancer (O.C) study with Taxotere (T). Proc Am Soc Clin Oncol 13:269, 1994 (abstr 859)
22. Rustin GJS, Crawford M, Lambert J, et al: Trial of oral Hexalen for relapsed ovarian carcinoma: Comparison of CA 125 and EORTC response definitions. Proc Am Soc Clin Oncol 14:269, 1995 (abstr 745)
23. van der Burg MEL, Myles JD, Hoskins PJ, et al: CA125 is an unreliable marker for monitoring response to Taxol therapy in patients with relapsed ovarian cancer. Eur J Cancer 29A:133, 1993 (suppl 6, abstr 723)